Pyxis Oncology

Pyxis Oncology

Biotechnology
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

$266.9M

Market Cap • 9/11/2026

2018

(8 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

23,3

P/S

P/EBITDA

P/OCF

P/FCF

P/E

BVPS

0,2

EPS

Market Cap

Market Cap

266,9M

EV

251,7M

EV/Revenue

0

EV/EBITDA

-2,9

EV/EBIT

-2,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-4,1%

Total Yield

-4,1%

Payout

0%

Retained Earnings

-491,8M

Profitability

Gross Margin

EBITDA Margin

EBIT Margin

Net Margin

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

% PPE

33,1%

% Goodwill

0%

ROE

ROIC

Growth

CAGR Op. Income 5Y

13,3%

CAGR Net Income 5Y

10,3%

CAGR EPS 5Y

-48,7%

CAGR OCF 5Y

25,6%

Leverage

N.D./EBITDA

0,2

Debt/Equity

0%

Current Ratio

1,3

Quick Ratio

1,2

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium